ANZCTR search results

This study aims to determine the safety, efficacy, and feasibility of sentinel lymph node biopsy for people with high risk non melanoma skin cancer. Who is it for? You can join this study if you are aged 18 years or more, have high risk non melanoma skin cancer, and will be available for a 5 year follow-up assessment. Trial details Participants in this trial will receive wide local excision of their skin cancer and sentinel lymph node biopsy (SLNB). SLNB is a procedure in which the local lymph node ("gland") that drain the patch of skin containing the tumour are excised. These lymph node(s) are examined under a microscope to determine whether cancer cells are present. If cancer cells are found, patients will undergo completion lymphadenectomy (i.e. surgical removal of the rest of the regional lymph nodes). This trial will evaluate the rates of positive sentinel lymph nodes in patients with high risk non melanoma skin cancer and assess morbidity or injury associated with the sentinel lymph node biopsy procedure.

This study aims to determine whether morphine reduces the feeling of breathlessness in patients with mesothelioma, asbestosis or interstitial lung disease. Who is it for? you can join this study if you are 18 years or more, and suffer from a feeling of breathlessness (dyspnoea) as a result of maximally treated mesothelioma, asbestosis, or interstitial lung disease. You must be able to speak English and should not be taking regular opioid medication (painkillers). Trial details Participants in this trial will be randomly (by chance) assigned to receive either 20mg sustained-release morphine (by oral capsule) together with a laxitive Coloxyl and Senna, or placebo (sham) tablets for one week. They will receive no medication for the second week and will then receive the alternate treatment ( morphine or placebo) for the third week. Participants will not know when they are taking the active drug or placebo. Participants will be asked to complete questionnaires and keep a diary over the 3 weeks of the trial to determine their response to treatment. They will also be phoned and visited at home by a nurse to monitor any side effects of treatment.

We hypothesise that multi-media patient education technology is superior to pamphlet delivery of this information. A secondary hypothesis is that increased understanding of epidural anaesthetic in labour will increase patient anxiety levels.

Diabetes and obesity are global pandemics. Currently more than 25% of the Australian population are obese and the prevalence of diabetes is one of the highest of any developed nation. There is an alarming increase in diabesity in younger people and thus younger patients with more aggressive disease will increasingly present for treatment, e.g. exercise therapy, respiratory management of acute and chronic disorders, and for assessment and treatment of diabetes complications. To date, no study has investigated lung function during exercise and/or the effect of co-morbid obesity on pulmonary function in patients with newly-diagnosed type 2 diabetes. Given the potential of newly-diagnosed patients to institute lifestyle change, and the aggressive nature of early-onset diabetes, this group represents an ideal target for preventive and ameliorative therapies. However, prior to evaluating effects of therapy (e.g. weight loss, exercise training, improved glycaemic control), baseline data are required. This pilot study is thus designed to provide evidence that will facilitate targeted design of a larger clinical intervention trial. This pilot study aims to quantify lung function at rest and during exercise in obese and non-obese patients with newly-diagnosed early-onset type 2 diabetes (T2D) compared with controls without diabetes.

This is an audit of patients who present to hospital with angioedema (swelling around the head and neck) associated with the use of a common blood pressure medication, the ACE inhibitors. The purpose is to try to determine how frequently this problem occurs across a range of hospitals, and also, to provide more information to enable an estimation of the proportion of cases where there is serious concern (ie threatened or real airway obstruction or death).

this study seeks to determine if minimially invasive monitors can detect blood loss in awake patients. Our hypothesis is that the monitors will be able to detect a known blood loss of 10% of estimated blood volume. We will test this by bleeding volunteers a known amount of blood and then looking to see if the monitors detect this blood loss.

The ingestion of nutrients induces a number of changes in gastrointestinal function which are associated with the modulation of appetite and energy intake. These changes include the slowing of gastric emptying, which sustains gastric distension and is associated with proximal gastric relaxation and changes in small intestinal motility. It has been established that fat and carbohydrate empty from the stomach at an overall rate of 1-3kcal/minute irrespective of volume, while the load of fat and carbohydrate is known to effect gastrointestinal motor activity and slow gastric emptying rate. To date, research documenting the gastric emptying rate of protein is limited and the effect of varying the protein load has not been characterised. Moreover, the relationship between gastric emptying and the regulation of energy intake by dietary protein remains unclear. Effects on gastrointestinal hormone release also occur with macronutrient ingestion. Small intestinal administration of fat has been shown to increase plasma CCK, PYY, and GLP-1 to a greater extent than carbohydrate in both healthy young and older men. However, evidence for load-dependent effects of protein on gut hormones is inconsistent. Since these gastrointestinal hormones have an important role in the regulation of appetite and energy intake, it is imperative that changes in the magnitude and temporal pattern of their release is established in response to varying protein loads and also related to changes in gastric emptying and intragastric meal distribution. Thus, this study has been designed to investigate how the load of orally administered Whey Protein Isolate effects gastric emptying rate, intragastric meal distribution, gut hormone concentrations, appetite sensations, and subsequent energy intake in healthy, lean individuals.

Constipation is a common, distressing and serious symptom, affecting between 50-90% of people referred to specialist palliative care services, with 40-70% of people failing to achieve adequate symptom control. The number of people failing to achieve satisfactory symptom relief is not acceptable as inadequate symptom relief is responsible for adding to individual and societal burdens. In palliative care, decisions regarding the prescription of laxatives are based predominantly on clinical experience and institutional approaches. Many of these do not consider the pathophysiological basis that underlies the symptom of constipation. This approach is very dissimilar to that adopted by gastroenterologists in the treatment of non-palliative care patients. The most striking difference is the limited information to categorise the palliative population into the groupings that gastroenterologists would routinely use, thereby limiting the ability to tailor interventions to improve symptom control. This study will aim 1). To develop an approach to constipation that enables the underlying problems (slow transit of colonic contents, delayed outlet of colonic contents or an overlap of these problems), to be quantified in palliative care patients using well-tolerated and validated diagnostic methods; 2). To compare whether the constipation severity of those patients randomly allocated to a mechanistic approach to the assessment and treatment of constipation within different sub categories have better patient outcomes than people palliated using standard current clinical care.

This project is examining the user-experience and evaluating Anxiety Online, an internet-based treatment clinic for consumers with anxiety symptoms and disorders. Consumers can complete a comprehensive psychological assessment (e-PASS), following which they receive a report which provides them with details as to the type and severity of their anxiety and other mental health problems and appropriate treatment recommendations. If they show symptoms of anxiety consumers have the option of completing a treatment program on their own or with email assistance from a therapist. Programs are available for generalised anxiety disorder, obsessive-compulsive disorder, panic disorder, with or without agoraphobia, post traumatic stress disorder and social anxiety disorder. Consumers are asked to complete e-PASS post-program (week 12) and invited to complete it yearly from 1-year post-program through to 5-year post-program. It is expected that at post-program consumers will show a reduction in the severity of their anxiety symptoms, K-6 scores and total number of clinical diagnoses/symptoms. In addition, it is expected that quality of life and confidence in managing one's own mental health care will increase at post-program.

Research suggests Brain Training may be effective for improving the brain’s ability to store and process information, and imaging studies suggest Brain Training may also lead to positive changes to brain structure and function . However, most of the research to date has simply measured effects by comparing data before and after a period of Brain Training. The effects of Brain Training during the training period has yet to be properly examined. We would therefore like to answer three main questions: 1. What is the minimum duration of Brain Training required to produce cognitive benefits? 2. By what rate do any positive cognitive effects decay after the cessation of Brain Training? 3. How do different brain changes (as revealed by brain imaging) develop over time?